Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLASSIA in Lung Transplantation
NCT02614872Phase 2Completed
- Sponsor
- Kamada Ltd.
- Start
- Jul 2016
- Primary completion
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of alpha1-proteinase inhibitor in lung transplant rejection, Bronchiolitis Obliterans Syndrome (BOS), sponsored by Kamada Ltd.. Started Jul 2016; status: completed.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
lung transplant rejectionBronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT02614872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02614872.